Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

11-04-2018 | Original Paper

A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder

Auteurs: Logan K. Wink, Ryan Adams, Paul S. Horn, Charles R. Tessier, Andrew P. Bantel, Michael Hong, Rebecca C. Shaffer, Ernest V. Pedapati, Craig A. Erickson

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 9/2018

Abstract

Riluzole is a glutamatergic modulator of particular interest in autism spectrum disorder (ASD). In this 12-week randomized, double-blind, placebo-controlled, crossover pilot study we evaluated the safety and tolerability of 5-week of adjunctive riluzole treatment (vs. 5-week of placebo, with 2-week washout period) targeting ASD-associated drug-refractory irritability in eight individuals age 12–25 years. All participants tolerated riluzole 200 mg per day, however there were no statistically significant findings for the overall treatment effect, the treatment effect by week within period of the study, or a cross-over effect across the periods of the study on the Clinical Global Impression Improvement Scale or the Aberrant Behavior Checklist Irritability subscale. The results of this trial indicate that 5-week of riluzole treatment was well tolerated, but had no significant effect on the target symptoms. Trial Registration ClinicalTrials.gov Identifier NCT02081027, Registered 5 August 2013, First participant enrolled 19 September 2013.

vorige artikel Autism Spectrum Symptomatology in Children with Williams Syndrome Who Have Phrase Speech or Fluent Language

volgende artikel Adults with Autism Tend to Undermine the Hidden Environmental Structure: Evidence from a Visual Associative Learning Task

Alleen toegankelijk voor geautoriseerde gebruikers

Adler, B. A., et al. (2014). Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study. Autism. https://doi.org/10.1177/1362361314524641.PubMed

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.

Christensen, D. L. (2016). Prevalence and characteristics of autism spectrum disorder among children aged 8 years- autism developmental disabilities monitoring network. Journal of Developmental & Behavioral Pediatrics 37, 1–8.CrossRef

Constantino, J., & Gruber, C. (2005). Social responsiveness scale. Torrance: WPS Publishing LLC.

Coric, V., et al. (2005). Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biological Psychiatry, 58, 424–428. https://doi.org/10.1016/j.biopsych.2005.04.043.CrossRefPubMed

Delahanty, R. J., et al. (2009). Maternal transmission of a rare GABRB3 signal peptide variant is associated with autism. Molecular Psychiatry. https://doi.org/10.1038/mp.2009.118.PubMedPubMedCentral

Doble, A. (1996). The pharmacology and mechanism of action of riluzole. Neurology, 47, S233–S241.CrossRef

Erickson, C. A., et al. (2011). Open-label riluzole in fragile X syndrome. Brain Research, 1380, 264–270. https://doi.org/10.1016/j.brainres.2010.10.108.CrossRefPubMed

Erickson, C. A., et al. (2017). Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism. Journal of Psychiatric Research, 84, 153–160. https://doi.org/10.1016/j.jpsychires.2016.09.003.CrossRefPubMed

Erickson, C. A., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2008). Glutamatergic function in autism. In U. Heresco-Levy (Ed.), Glutamate in neuropsychiatric disorders. (pp. 197–212). Trivandrum: Research Signpost.

Faridar, A., et al. (2014). Mapk/Erk activation in an animal model of social deficits shows a possible link to autism. Molecular Autism, 5, 57. https://doi.org/10.1186/2040-2392-5-57.CrossRefPubMedPubMedCentral

Fatemi, S. H., Halt, A. R., Stary, J. M., Kanodia, R., Schulz, S. C., & Realmuto, G. R. (2002). Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biological Psychiatry, 52, 805–810.CrossRefPubMed

Fatemi, S. H., Reutiman, T. J., Folsom, T. D., & Thuras, P. D. (2009). GABA(A) receptor downregulation in brains of subjects with autism. Journal of Autism and Developmental Disorders, 39, 223–230. https://doi.org/10.1007/s10803-008-0646-7.CrossRef

Fumagalli, E., Funicello, M., Rauen, T., Gobbi, M., & Mennini, T. (2008). Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. European Journal of Pharmacology, 578, 171–176. https://doi.org/10.1016/j.ejphar.2007.10.023.CrossRefPubMed

Grant, P., Lougee, L., Hirschtritt, M., & Swedo, S. (2007a). An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology, 17, 761–767.CrossRefPubMed

Grant, P., Lougee, L., Hirschtritt, M., & Swedo, S. E. (2007b). An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Journal of Child Adolescent Psychopharmacology, 17, 761–767. https://doi.org/10.1089/cap.2007.0021.CrossRefPubMed

Grant, P. J., et al. (2014). 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology, 39, 1453–1459. https://doi.org/10.1038/npp.2013.343.CrossRefPubMedPubMedCentral

Guy, W. (1976). ECDEU assessment manual for psychopharmacology. Washington DC: National Institute of Mantal Health, U.S. Department of Helath, Education and Wellfare.

He, Y., et al. (2002). Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology, 42, 199–209.CrossRefPubMed

Hogart, A., Nagarajan, R. P., Patzel, K. A., Yasui, D. H., & Lasalle, J. M. (2007). 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Human Molecular Genetics, 16, 691–703. https://doi.org/10.1093/hmg/ddm014.CrossRefPubMedPubMedCentral

Jahn, K., Schlesinger, F., Jin, L. J., Dengler, R., Bufler, J., & Krampfl, K. (2008). Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABA(A)-receptors. Naunyn-Schmiedeberg’s Archives of Pharmacology, 378, 53–63. https://doi.org/10.1007/s00210-008-0290-y.CrossRefPubMed

Kim, S. A., Kim, J. H., Park, M., Cho, I. H., & Yoo, H. J. (2006). Association of GABRB3 polymorphisms with autism spectrum disorders in Korean trios. Neuropsychobiology, 54, 160–165. https://doi.org/10.1159/000098651.CrossRefPubMed

Lecavalier, L., Leone, S., & Wiltz, J. (2006). The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. Journal of Intellectual Disability Research, 50, 172–183. https://doi.org/10.1111/j.1365-2788.2005.00732.x.CrossRef

Lord, C., Rutter, M., DiLavore, P., Risis, S., Gotham, K., & Bishop, S. (2012). Autism diagnostic observation schedule (ADOS-2), (2nd ed). Portland: Western Psychological Services.

Malhotra, D., & Sebat, J. (2012). CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell, 148, 1223–1241. https://doi.org/10.1016/j.cell.2012.02.039.CrossRefPubMedPubMedCentral

Marcus, R. N., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1110–1119. https://doi.org/10.1097/CHI.0b013e3181b76658.CrossRefPubMed

McCracken, J. T., et al. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine 347, 314–321.CrossRef

Menold, M. M., et al. (2001). Association analysis of chromosome 15 gabaa receptor subunit genes in autistic disorder. Journal of Neurogenetics, 15, 245–259. https://doi.org/10.3109/01677060109167380.CrossRefPubMed

Owen, R., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540.CrossRefPubMed

Page, L. A., et al. (2006). In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. American Journal of Psychiatry, 163, 2189–2192. https://doi.org/10.1176/appi.ajp.163.12.2189.CrossRefPubMed

Pittenger, C., Kelmendi, B., Wasylink, S., Bloch, M. H., & Coric, V. (2008). Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A series of 13 cases, with long-term follow-up. Journal of Clinical Psychopharmacology, 28, 363–367. https://doi.org/10.1097/JCP.0b013e3181727548.CrossRefPubMed

Posey, D. J., Stigler, K. A., Erickson, C. A., & McDougle, C. J. (2008). Antipsychotics in the treatment of autism. Journal of Clinical Investigation, 118, 6–14. https://doi.org/10.1172/JCI32483.CrossRefPubMed

Pucilowska, J., Vithayathil, J., Tavares, E. J., Kelly, C., Karlo, J. C., & Landreth, G. E. (2015). The 16p11.2 deletion mouse model of autism exhibits altered cortical progenitor proliferation and brain cytoarchitecture linked to the ERK MAPK pathway. The Journal of Neuroscience 35, 3190–3200. https://doi.org/10.1523/JNEUROSCI.4864-13.2015.CrossRef

Purcell, A. E., Jeon, O. H., Zimmerman, A. W., Blue, M. E., & Pevsner, J. (2001). Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology, 57, 1618–1628.CrossRefPubMed

Samuels, I. S., et al. (2008). Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. The Journal of Neuroscience, 28, 6983–6995. https://doi.org/10.1523/JNEUROSCI.0679-08.2008.CrossRefPubMedPubMedCentral

Samuels, I. S., Saitta, S. C., & Landreth, G. E. (2009). MAP’ing CNS development and cognition: An ERKsome process. Neuron, 61, 160–167. https://doi.org/10.1016/j.neuron.2009.01.001.CrossRefPubMedPubMedCentral

Sanacora, G., Kendell, S. F., Fenton, L., Coric, V., & Krystal, J. H. (2004). Riluzole augmentation for treatment-resistant depression. American Journal of Psychiatry, 161, 2132. https://doi.org/10.1176/appi.ajp.161.11.2132.CrossRefPubMed

Scahill, L., et al. (2006). Children’s yale-brown obsessive compulsive scale modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1114–1123. https://doi.org/10.1097/01.chi.0000220854.79144.e7.CrossRefPubMed

Siegel, M., et al. (2015). The autism inpatient collection: Methods and preliminary sample description. Molecular Autism 6, 61 https://doi.org/10.1186/s13229-015-0054-8.CrossRefPubMedPubMedCentral

Wang, S. J., Wang, K. Y., & Wang, W. C. (2004). Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience, 125, 191–201. https://doi.org/10.1016/j.neuroscience.2004.01.019.CrossRefPubMed

Weng, N., Weiler, I. J., Sumis, A., Berry-Kravis, E., & Greenough, W. T. (2008). Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B, 1253–1257. https://doi.org/10.1002/ajmg.b.30765.CrossRef

Wink, L. K., et al. (2017). Characterization of medication use in a multicenter sample of pediatric inpatients with autism spectrum disorder. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-017-3153-x.

Wink, L. K., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2011). Riluzole in autistic disorder. Journal of Child and Adolescent Psychopharmacology, 21, 375–379. https://doi.org/10.1089/cap.2010.0154.CrossRefPubMed

Wink, L. K., Pedapati, E. V., Horn, P. S., McDougle, C. J., & Erickson, C. A. (2015). Multiple antipsychotic medication use in autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, https://doi.org/10.1089/cap.2015.0123.PubMedCentral

Zarate, C. A. Jr., et al. (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. American Journal of Psychiatry, 161, 171–174.CrossRefPubMed

Zarate, C. A. Jr., et al. (2005). An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biological Psychiatry, 57, 430–432. https://doi.org/10.1016/j.biopsych.2004.11.023.CrossRefPubMed

Titel: A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder
Auteurs: Logan K. Wink
Ryan Adams
Paul S. Horn
Charles R. Tessier
Andrew P. Bantel
Michael Hong
Rebecca C. Shaffer
Ernest V. Pedapati
Craig A. Erickson
Publicatiedatum: 11-04-2018
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 9/2018
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-018-3562-5

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 9/2018

Older Adults with Autism Spectrum Disorders in Sweden: A Register Study of Diagnoses, Psychiatric Care Utilization and Psychotropic Medication of 601 Individuals

Brief Report: Memory for Self-Performed Actions in Adults with Autism Spectrum Disorder: Why Does Memory of Self Decline in ASD?

Construction of Past and Future Events in Children and Adolescents with ASD: Role of Self-relatedness and Relevance to Decision-Making

Differences Between the Childhood Autism Rating Scale and the Social Responsiveness Scale in Assessing Symptoms of Children with Autistic Spectrum Disorder

Efficacy of the ASAP Intervention for Preschoolers with ASD: A Cluster Randomized Controlled Trial

Higher Autistic Traits Among Criminals, But No Link to Psychopathy: Findings from a High-Security Prison in Portugal